'Very, very luckily for me, this project is going well'

Five questions with glycobiologist Vijayakanth Pagadala
Laurel Oldach
Aug. 13, 2021

Vijayakanth Pagadala was a postdoc in Jian Liu’s lab at the University of North Carolina at Chapel Hill when he got an exciting opportunity: running the science at Liu’s startup, Glycan Therapeutics. He’s been there for five and a half years, working on in vitro production of a glycan drug that currently comes from animal sources. This interview has been condensed and edited.


Name: Vijayakanth Pagadala

Current position: Principal scientist, Glycan Therapeutics

Career path: Ph.D.: Rosalind Franklin University, 2009
Postdoctoral research: National Institute of Environmental Health Sciences, 2009-2013; University of North Carolina at Chapel Hill, 2013-2015

Favorite molecule: Adenosine triphosphate synthase. “It is the most fascinating molecule.”

Glycan makes synthetic oligosaccharides. What are they useful for?

We’re trying to produce synthetic heparin. Heparin is the oldest and best known anticoagulant, a blood-thinner injectable that is purified from animal gut. It is made from cheap, easily available raw material, manufactured on a scale of tons. But there have been instances where contaminated heparin killed people. Also, 80% of global heparin comes from pigs, and swine flu is decimating the pig population, which risks the supply chain. Pharmacologically, the synthetic drug we are making is a single-molecule entity, whereas heparin is a mixture of approximately 30 different oligosaccharides.

Do you spend most of your time engineering heparin and heparin-producing enzymes?

I want to spend more time on engineering, but there are some financial and deliverable constraints that won’t let me. I am working on optimizing production: how to grow cells, how much protein we get out of each batch, how much starting material we can convert into product, how many rounds of synthesis we can do in a year and so on. I do some process engineering, some enzyme engineering and strain screening. In the near future, I hope that we’ll tie up with some bioprocessing giant where enzyme engineering and production is a push of a button.

What made you want to work at a startup?

A confluence of factors and being in the right place at the right time. I’m happy I made the choice to join a startup. Very, very luckily for me, this project is going well. Unfortunately, only one in 10 postdocs get a chance for an equitable share of the academic research pie. I think I will continue to be in entrepreneurship, because you can come out with real, life-changing products.

You’re the PI on a couple of Small Business Innovation Research grants. How do they compare to academic funding?

In a way, there is a simpler scientific goal in the SBIRs. But reproducibility, scalability and execution have to be 100% or else the product will fail. The emphasis is on execution and commercialization rather than proof of concept.

What skills have you needed to develop on the job?

People skills. You can work in relative isolation in a big lab. But in a small startup where you build everything from scratch, everybody in the team has to work with each other and wear multiple hats. Academics do wear a lot of hats, but, generally, people skills are less important in an academic lab. Also, a deep-seated can-fix-anything mentality is critical for navigating the demands of a job in a startup.

(Would you like to suggest an ASBMB member who works in industry for a Five Questions interview? Send an email to ASBMB Today.)

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Featured jobs

from the ASBMB career center

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Industry

Industry highlights or most popular articles

A turbulent industry: 5 questions with Paul Wright

A turbulent industry: 5 questions with Paul Wright

Sept. 10, 2021

Paul Wright, a chemist whose 28-year career in the pharmaceutical industry spanned many types of roles and companies, shares what he learned along the way with ASBMB Today.

What we’ve learned about careers in industry

What we’ve learned about careers in industry

Aug. 6, 2021

Industry careers columnist Courtney Chandler and staff writer Laurel Oldach team up to offer advice for job seekers.

Biotech industry jargon: A primer for the curious
Professional Development

Biotech industry jargon: A primer for the curious

July 29, 2021

The specific scientific and technical knowledge you need in an industry job depends on the role and will change over the course of your career. But it can help to know the basics.

A primer on performance reviews in industry

A primer on performance reviews in industry

July 16, 2021

Our industry careers columnist provides an overview of what you can expect and how to handle a lukewarm or negative review.

Why is the FDA funded in part by the companies it regulates?

Why is the FDA funded in part by the companies it regulates?

July 4, 2021

The U.S. Food and Drug Administration receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?

Out for blood in the search to stall aging

Out for blood in the search to stall aging

July 3, 2021

A gaggle of biotech startups are trying vastly different approaches to spin animal studies into the next big anti-aging therapy. It’s too early to know which, if any, will succeed.